A New Convenient Oral Alternative
Current therapeutic approaches to treat cardiometabolic disease are fraught with challenges to the patient and to the medical profession. Treatments for high cholesterol and diabetes, while mostly effective, are not universally tolerated. Statins provide significant improvement by reducing cholesterol and cardiovascular risk but there are still unmet needs. Approximately one-quarter of patients do not tolerate statins (Can J Cardiol. 2011 Sep;27(5):635-62), and research has found that after two years of taking statins, around half of patients hadn’t met the target for lowering cholesterol. A major problem with currently used drugs for diabetes is that they have side effects, some very serious, which have led to restrictions in their use. Furthermore, those drugs are not fully effective and their efficacy wanes over time. Additionally, most of them do not address insulin resistance, which leads to many comorbidities including cardiovascular disease and NASH (non-alcoholic steatohepatitis). The result is the need to use combinations of two or more drugs to control diabetes. Some of the newer, more effective drugs are injectable, and therefore are inconvenient to administer and expensive to manufacture.
BioKier’s novel products are orally administered, can be approved via the 505(b)(2) regulatory pathway, and will restore gut hormone secretion in patients who need to improve cholesterol levels and insulin sensitivity to manage their glucose better.